Thermo Fisher Scientific(US:TMO) Xin Lang Cai Jing·2026-02-15 21:17Company Performance Goals - Management has provided guidance for 2026, expecting revenue growth of 3.9% to 5.9% year-over-year and adjusted EPS growth of 5.9% to 8.4%, reaffirming a long-term organic revenue growth target of 3%-6% [1] Strategic Advancements - In 2025, the company completed the acquisition of Solventum's filtration and separation business and a sterile filling facility from Sanofi in New Jersey. In Q4 2025, it announced a proposed $8.9 billion acquisition of clinical data service provider Clario, aimed at enhancing biomanufacturing and localization capabilities. The market will focus on the synergies and integration effects of these acquisitions [2] Business Progress - The Life Sciences Solutions segment saw a profit increase of 7.6% in 2025, becoming a core growth engine, while the analytical instruments segment experienced an 11.2% profit decline. The company continues to launch new technology products, such as the Orbitrap Astral mass spectrometer, and has partnered with Open AI and the Chan Zuckerberg Initiative to promote the application of artificial intelligence in operations [3] Industry Conditions - According to a report by CMB International, demand from pharmaceutical and biotechnology clients is rebounding in 2025, with high single-digit revenue growth in Q4. The recovery in biotechnology financing may translate into order increases in the next 6-12 months, potentially driving revenue growth [4]